Clinical Trials on Solid Tumors and Hematologic Malignancy in New Zealand

Total 6123 results

Immunocore Ltd

Terminated

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Select Advanced Solid Tumors

United States, United Kingdom, Spain
Memorial Sloan Kettering Cancer Center

Terminated

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Non-Malignant Hematologic Disorders

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Northwestern University
National Cancer Institute (NCI); Hackensack Meridian Health; Lombardi Comprehensive...

Completed

Expressive Helping for Stem Cell Transplant Patients

Stem Cell Transplantation | Hematologic Malignancy

United States
Shionogi

Completed

A Phase 1 Study of S-3304 in Patients With Solid Tumors

Solid Tumors

United States
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel

Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China, Taiwan
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Solid Tumors

United States, Australia, Spain, Germany, France, Switzerland, Netherlands, Canada, Belgium, Italy
Gilead Sciences

Completed

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Solid Tumor

United States
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
Immunocore Ltd

Terminated

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Select Advanced Solid Tumors

United States, Canada, United Kingdom
Aprea Therapeutics

Recruiting

Study Of ATRN-119 In Patients With Advanced Solid Tumors (ABOYA-119)

Advanced Solid Tumor

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Green Tea Extract in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Aptose Biosciences Inc.

Completed

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

Advanced or Metastatic Solid Tumours

United States
Eli Lilly and Company

Terminated

A Study of LY3405105 in Participants With Advanced Cancer

Solid Tumor

United States, France, Spain, Taiwan, Canada
Hoffmann-La Roche

Completed

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.
Atridia Pty Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumors

China, Korea, Republic of, Taiwan, United States, Australia
MedImmune LLC

Completed

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of
Kadmon, a Sanofi Company

Terminated

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

United States
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) (COMBO)

Advanced Solid Tumors

Spain, United States, Netherlands, Hungary, Italy, France, Belgium
MedImmune LLC

Terminated

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Cancer | Solid Tumors | CTCL

United States, France, Canada
CStone Pharmaceuticals

Terminated

A Study of CS3002 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
AVEO Pharmaceuticals, Inc.

Terminated

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Solid Tumors

United States, Canada, Netherlands, India, Russian Federation, Ukraine
Merck Sharp & Dohme LLC

Terminated

A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Advanced Solid Tumors

Canada, United States, Denmark, Israel, Switzerland
OncoMed Pharmaceuticals, Inc.
Celgene Corporation

Completed

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

Poland, Korea, Republic of, United States, Argentina, Australia, Canada, Colombia, France, Germany, Guatemala, Israel, Italy, Japan, Latvia, Mexico, Peru, Puerto Rico, Romania, South Africa, Spain, Sweden, Turkey, Ukraine
Omico
Hoffmann-La Roche; The George Institute for Global Health, Australia

Recruiting

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)

Solid Tumor, Adult

Australia
Bristol-Myers Squibb

Terminated

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors (CXCessoR4)

Solid Tumor

United States, Finland
U3 Pharma GmbH

Completed

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Genmab
BioNTech SE

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Solid Tumor, Adult

Spain, United States
Memorial Sloan Kettering Cancer Center
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Malignant Peripheral Nerve Sheath Tumors (MPNST)

United States
Roswell Park Cancer Institute
Abbott

Completed

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
Y-mAbs Therapeutics

Terminated

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Osteosarcoma | Neuroblastoma | Other Solid Tumor Cancers

United States
Leap Therapeutics, Inc.

Completed

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Solid Tumors

United States
Genentech, Inc.

Completed

Study of Cobimetinib in Participants With Solid Tumors

Solid Tumor

United States
Shanghai YingLi Pharmaceutical Co. Ltd.
Yingli Pharma US, Inc

Recruiting

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Advanced Solid Tumor

United States
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Roswell Park Cancer Institute
Novartis

Completed

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute

Completed

Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States

Clinical Trials on Solid Tumors and Hematologic Malignancy in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations